查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1592899

小儿惊厥治疗药物市场：依剂量、给药途径- 全球预测 2025-2030 年

Infantile Spasms Therapeutics Market by Dosage (Liquid, Solid), Route of Administration (Oral, Parental) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年小儿惊厥治疗市场价值为3.8175亿美元，预计到2024年将达到4.0601亿美元，复合年增长率为6.44%，预计到2030年将达到5.9124亿美元。

儿科癫痫治疗市场包括开发、生产和分销用于管理和缓解儿科癫痫症状的治疗方法，儿科癫痫是一种影响婴幼儿和幼儿的罕见神经系统疾病。这个市场包括旨在改善患者预后的药物、饮食疗法和手术干预。对这些疗法的需求源于解决与未经治疗的癫痫发作相关的发育迟缓和神经缺陷的迫切需求。典型应用包括抗癫痫药物、荷尔蒙疗法和生酮饮食管理，最终用户包括医院、诊所和专业医学研究中心。该市场的主要成长要素是人们对该疾病的认识不断提高以及医疗诊断和影像技术的进步。对罕见疾病的监管激励措施和增加对儿科神经病学研究的投资正在进一步支持市场成长。新的商机在于优化基因治疗、探索生物製药解决方案以及利用人工智慧进行早期准确诊断。公司可以透过加强研发力度、建立策略合作伙伴关係以及创新治疗方法来抓住这些机会，以满足未满足的需求。然而，该市场面临着治疗成本高、由于疾病稀有而导致患者数量有限以及严格的监管障碍等挑战。提高我们对儿童癫痫发作遗传基础的理解并投资精准医疗可能是一个有希望的创新领域。专注于开发针对特定症状的治疗方法和整合远端医疗解决方案以进行持续监控的公司将获得显着的成长和差异化。这个市场的性质是高度专业化的，由尖端研究和开发驱动，需要在临床试验和监管合规方面进行大量投资。然而，专注于策略伙伴关係和技术进步可以释放这一利基治疗领域的巨大潜力。

主要市场统计
基准年[2023] 38175万美元
预测年份 [2024] 40601万美元
预测年份 [2030] 5.9124 亿美元
复合年增长率（%） 6.44%

市场动态：快速发展的儿科癫痫药物市场的关键市场洞察

供需的动态交互作用正在改变儿科癫痫药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 中枢神经系统 (CNS)感染疾病盛行率增加
    • 儿童癫痫药物的使用率不断增加
    • 政府和私人组织提高意识以减少未确诊病例的数量
  • 市场限制因素
    • 儿童惊厥的治疗费用不断上升且缺乏正确的诊断
  • 市场机会
    • 扩大儿科癫痫治疗的科学进展
    • 增加广泛的研发活动
  • 市场挑战
    • 药品核准严格规定

波特五力：驾驭儿科癫痫药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解小儿惊厥治疗市场的外在影响

外部宏观环境因素在塑造小儿惊厥治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解小儿惊厥治疗药物市场的竞争状况

对小儿惊厥治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵小儿惊厥治疗药物市场供应商的绩效评估

FPNV 定位矩阵是评估小儿惊厥治疗药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划小儿惊厥治疗药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对小儿惊厥治疗药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 中枢神经系统 (CNS)感染疾病盛行率增加
      • 癫痫药物的普及率不断上升
      • 政府和私人组织为减少未确诊病例数而进行的宣传活动
    • 抑制因素
      • 癫痫治疗费用高且缺乏适当的诊断
    • 机会
      • 扩大癫痫治疗的科学进步
      • 扩大广泛的研究和开发活动
    • 任务
      • 药品核准严格规定
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章小儿惊厥治疗药物市场按剂量

  • 液体
  • 固体的

第七章小儿惊厥治疗药物市场：依途径

  • 口服
  • 监护人

第八章北美和南美小儿癫痫治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区小儿惊厥治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲小儿惊厥治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Anavex Life Sciences Corp.
  • Cerecin Inc.
  • H. Lundbeck A/S
  • Lupin Limited
  • Mallinckrodt Pharmaceuticals
  • MSN Laboratories Private Limited
  • ORPHELIA Pharma
  • Ovid Therapeutics Inc.
  • Zydus Group
Product Code: MRR-43127F727967

The Infantile Spasms Therapeutics Market was valued at USD 381.75 million in 2023, expected to reach USD 406.01 million in 2024, and is projected to grow at a CAGR of 6.44%, to USD 591.24 million by 2030.

The scope of the Infantile Spasms Therapeutics market entails the development, production, and distribution of treatments designed to manage and alleviate symptoms of infantile spasms, a rare neurological disorder affecting infants. It involves pharmaceuticals, dietary treatments, and surgical interventions aimed at improving patient outcomes. The necessity of these therapeutics stems from the critical need to address developmental delays and neurological deficits associated with untreated spasms. Key applications include antiepileptic drugs, hormone therapy, and ketogenic diet management, with end-users encompassing hospitals, clinics, and specialized medical research centers. A major growth factor in this market is the increasing awareness of the disorder and advancements in medical diagnostics and imaging technologies. Regulatory incentives for rare diseases and the rising investment in pediatric neurology research further propel market growth. Emerging opportunities lie in optimizing gene therapy, exploring biopharmaceutical solutions, and leveraging AI for early and precise diagnosis. Businesses can capture these opportunities by intensifying R&D efforts, forging strategic collaborations, and addressing unmet needs with innovation in treatment delivery. However, the market faces challenges such as high costs of treatment, limited patient pool due to the rarity of the condition, and stringent regulatory hurdles. Nurturing an understanding of the genetic basis of infantile spasms and investing in precision medicine can be promising areas of innovation. Companies focusing on developing symptom-specific therapies and integrating telehealth solutions for continued monitoring could realize substantial growth and differentiation. The nature of the market is highly specialized, driven by cutting-edge research and development, and it demands significant investment in clinical trials and regulatory compliance. Nonetheless, with an emphasis on strategic partnerships and technological advancements, businesses can unlock substantial potential within this niche therapeutic arena.

KEY MARKET STATISTICS
Base Year [2023] USD 381.75 million
Estimated Year [2024] USD 406.01 million
Forecast Year [2030] USD 591.24 million
CAGR (%) 6.44%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Infantile Spasms Therapeutics Market

The Infantile Spasms Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of central nervous system (CNS) infection
    • Rising penetration rate of infantile spasm drugs
    • Awareness by government and private organizations to decrease the number of undiagnosed cases
  • Market Restraints
    • High cost of treatment and lack of proper diagnosis of infantile spasm
  • Market Opportunities
    • Expanding scientific advancements in the treatment for infantile spasms
    • Increasing extensive research and development activities
  • Market Challenges
    • Stringent regulations for drug approval

Porter's Five Forces: A Strategic Tool for Navigating the Infantile Spasms Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Infantile Spasms Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Infantile Spasms Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Infantile Spasms Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Infantile Spasms Therapeutics Market

A detailed market share analysis in the Infantile Spasms Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Infantile Spasms Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Infantile Spasms Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Infantile Spasms Therapeutics Market

A strategic analysis of the Infantile Spasms Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Infantile Spasms Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Anavex Life Sciences Corp., Cerecin Inc., H. Lundbeck A/S, Lupin Limited, Mallinckrodt Pharmaceuticals, MSN Laboratories Private Limited, ORPHELIA Pharma, Ovid Therapeutics Inc., and Zydus Group.

Market Segmentation & Coverage

This research report categorizes the Infantile Spasms Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Dosage, market is studied across Liquid and Solid.
  • Based on Route of Administration, market is studied across Oral and Parental.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of central nervous system (CNS) infection
      • 5.1.1.2. Rising penetration rate of infantile spasm drugs
      • 5.1.1.3. Awareness by government and private organizations to decrease the number of undiagnosed cases
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and lack of proper diagnosis of infantile spasm
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding scientific advancements in the treatment for infantile spasms
      • 5.1.3.2. Increasing extensive research and development activities
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations for drug approval
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Infantile Spasms Therapeutics Market, by Dosage

  • 6.1. Introduction
  • 6.2. Liquid
  • 6.3. Solid

7. Infantile Spasms Therapeutics Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parental

8. Americas Infantile Spasms Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Infantile Spasms Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Infantile Spasms Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Anavex Life Sciences Corp.
  • 2. Cerecin Inc.
  • 3. H. Lundbeck A/S
  • 4. Lupin Limited
  • 5. Mallinckrodt Pharmaceuticals
  • 6. MSN Laboratories Private Limited
  • 7. ORPHELIA Pharma
  • 8. Ovid Therapeutics Inc.
  • 9. Zydus Group

LIST OF FIGURES

  • FIGURE 1. INFANTILE SPASMS THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. INFANTILE SPASMS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. INFANTILE SPASMS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INFANTILE SPASMS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INFANTILE SPASMS THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SOLID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY PARENTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. INFANTILE SPASMS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. INFANTILE SPASMS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023